Capital raise. Quarter is over.
What's first, the CR, potential FDA approval does it matter? Worty the gamble whats first? If so whats the likely outcome with each scenario? Better waiting on FDA and seeing a small increase once a sure thing and buying then, or for the CR and the SP hammered and buying cheap (or offloading now, derisking, and buying in lower).
EITHER WAY - no revenue, no cash, loads more shares about to be issued at significant discount (What was it last time, 30% down to 4.5c? Much lower this time). Recent swag of 'announcements' smells of desperate attempt to get SP up a little before the CR.
Meanwhile an insti happy to offload at 0.6c even with a potential FDA approval tells you something. Theyll just pick up loads more in the CR which they must think is about to hit, and flog off again like they are doing now for easy money.
Oh yeah, if it does go anywhere we have the CEOs gift of a 5% dilution to help keep a price ceiling on this anyway.
Add to My Watchlist
What is My Watchlist?
